Vitamin K2 is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity and athletic performance.
Primarily, Vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy ageing. Kappa’s K2VITAL branded Vitamin K2 is the leading synthetic Vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio.
Egil Greve, Kappa Bioscience President and CEO, said: “We are extremely excited to join Balchem, a market leader in human nutrition and health and a science-driven company that aligns well with our vision to improve the quality of life for all."
"Our partners can expect continued expert knowledge, scientific excellence, product safety and quality and customer service as we further strengthen these areas together with Balchem. Our two companies are very complementary to each other."
"Balchem’s strength in the United States will further accelerate the growth of Kappa’s vitamin K2 platform in the United States. At the same time, Kappa provides Balchem with increased access to European markets. Both companies share a passion for science-based nutrition solutions while operating to the highest standards of integrity.”
Ted Harris, Chairman, CEO and President of Balchem, said: “This acquisition accelerates our strategy to expand our portfolio of science-based specialty nutrients with leading positions in expanding markets. Vitamin K2 fits squarely with our strategic focus and our vision of making the world a healthier place."
"Kappa Bioscience is the leader within its space and the only company offering a patented, 99.7% all-trans vitamin K2 as MK-7, identical to the bioactive K2 molecule found in nature."
"We are very pleased to welcome Kappa’s experienced team to Balchem and envision an accelerated growth trajectory across both companies’ human nutrients portfolios by combining our scientific and technical expertise, geographic reach, and marketplace leadership.”
Balchem has acquired Kappa from majority owner Verdane Edda for an enterprise value of NOK 3.175B (approximately USD 338M). Kappa will be included in Balchem’s Human Nutrition and Health business segment.